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Abstract
Background: The rise of systems biology and availability of highly curated gene and molecular information
resources has promoted a comprehensive approach to study disease as the cumulative deleterious function of a
collection of individual genes and networks of molecules acting in concert. These “human disease networks” (HDN)
have revealed novel candidate genes and pharmaceutical targets for many diseases and identified fundamental
HDN features conserved across diseases. A network-based analysis is particularly vital for a study on polygenic
diseases where many interactions between molecules should be simultaneously examined and elucidated. We
employ a new knowledge driven HDN gene and molecular database systems approach to analyze Inflammatory
Bowel Disease (IBD), whose pathogenesis remains largely unknown.
Methods and Results: Based on drug indications for IBD, we determined sibling diseases of mild and severe
states of IBD. Approximately 1,000 genes associated with the sibling diseases were retrieved from four databases.
After ranking the genes by the frequency of records in the databases, we obtained 250 and 253 genes highly
associated with the mild and severe IBD states, respectively. We then calculated functional similarities of these
genes with known drug targets and examined and presented their interactions as PPI networks.
Conclusions: The results demonstrate that this knowledge-based systems approach, predicated on functionally
similar genes important to sibling diseases is an effective method to identify important components of the IBD
human disease network. Our approach elucidates a previously unknown biological distinction between mild and
severe IBD states.
Keywords: Inflammatory bowel disease (IBD), Disease related genes, Protein-protein interaction networks, GO
based functional score, Interpretation of pathogenesis
Background
Inflammatory Bowel Disease (IBD) is a chronic disease of
unknown etiology that causes inflammation and ulcer in
intestinal mucosa. Although IBD is still much less prevalent
in Japan than in Western countries, the number of Japanese
IBD patients has rapidly increased in the last 20 years [1].
This rising trend, also observed in the Asia-Pacific region
[2,3] indicates that IBD is rapidly becoming a world-wide
disease. There are two major sub-categories of IBD:
Crohn’s disease (CD) and ulcerative colitis (UC) [4].
Although the pathogenesis of IBD is not fully explained,
genetic factors are suggested to contribute to dysregulation
of intestinal immunity, leading to gastrointestinal injury.
A genetic study of IBD was first reported in 1988 as an
epidemiological study of CD patients [5]. Genome-wide
scanning (GWS) studies have revealed nine IBD suscept-
ibility loci (IBD1-9) [6] and one susceptibility gene (NOD2)
[7]. Genome-Wide Association Studies (GWAS) and corre-
sponding meta-analyses identified 71 susceptibility loci for
CD [8] and 47 loci for UC [9]. Recently the genetic sus-
ceptibility to IBD was comprehensively reviewed in [10].
Another study based on and analysis of molecular path-
ways suggested a significant overlap between IBD and
autoimmune disorder, type 1 diabetes, ankylosing spondyli-
tis (AS), multiple sclerosis, asthma [11], and rheumatoid
arthritis (RA) [12].
IBD medical treatment policy and drug selection is
determined according to IBD ‘severity’ (mild, moderate,
or severe) [4,13-15], which reflects the frequency of rectal
bleedings and stools as well as mucosal appearances on
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any medium, provided the original work is properly cited.sigmoidoscopy. Aminosalicylate (e.g., Mesalazine) is a pri-
mary drug for the mild state, and anti-TNF antibody (e.g.,
Infliximab) is a primary drug for the severe state. Both
drugs act on inhibition of inflammatory cascades; how-
ever, while the anti-TNF antibody specifically interacts
with TNF, aminosalicylate is similar to other members of
nonsteroidal anti-inflammatory drugs (NSAIDs) having
several molecular targets.
Recently, human diseases have been studied with a sys-
tems approach to address the need to understand the
network of genes and molecules acting in concert to pro-
duce the pathogenesis and progression of the disease. A
human disease network (HDN) is a representation of the
etiology of the disease by protein-protein interaction
(PPI) data and information. Goh et al. constructed a
comprehensive HDN to cover all diseases and showed
that essential human genes encoded hub proteins in the
network [16]. Hase et al. investigated physical properties
of the comprehensive HDN, and elucidated that there
were extensive interconnections among middle-degree
nodes that formed the backbone of the network [17].
Hase et al. also investigated drug-target genes in the
HDN, and found significant preference of drug targets
for middle- and low-degree nodes [17].
Wall et al. studied the HDN for autism. They con-
structed the network by genes related to autism and other
neurological disorders in order to elucidate common fea-
tures in the diseases [18]. They identified 154 genes not
previously linked to autism. Based on this study, Wall
et al. developed a web tool for comprehensive genetic
annotation of diseases called “Genotator” [19]. Genotator
provides an up-to-date and comprehensive collection of
disease genes and a reliable gene-to-disease ranking for
any disease. They showed that the integration of all the
available databases gave a more complete picture than any
one database alone, using Alzheimer disease as a case
study.
The idea of Genotator inspired us to investigate IBD by
a knowledge driven HDN gene and molecular database
systems approach. Like autism and Alzheimer disease, IBD
is known to be a complex disease with a large number of
genes and molecules implicated in the etiology of the dis-
ease but without direct experimental evidence. A primary
difference between our approach and Wall’s is our use of
available drugs, their targeted pathways and genes and
related drug treatment information to highlight the more
important genes to the disease (in this case IBD). We
assume that current effective drug treatments and their
targets provide essential information that will help identify
key pathways important in the pathogenesis and progres-
sion of the disease. We collected genes related to IBD and
its drugs, constructed a disease network with the genes,
and investigated the functional similarity of drug targets to
the putative IBD genes. The human disease network
results demonstrate a new approach to characterizing IBD
and its progression from early stage into the chronic and
more malignant state.
Methods
Drug information on IBD and sibling diseases
We use the World Gastroenterology Organization [4]
guidelines and IBD societies of USA [20], Europe [21-24],
and Asia [2,3] to identify drugs for IBD and sibling dis-
eases. Additional drug information was collected from
PubMed and the Cochrane Library databases. The drug
indications were investigated by databases: Package Inserts
Database (in Japanese) [25] for Japanese drugs, FDA
Approved Drug Products [26] for US drugs, and the elec-
tronic Medicines Compendium (eMC) [27] for UK drugs.
Thereafter, target molecules and pathways of a drug were
retrieved from the DrugBank database [28]. We then
selected a target molecule of all the drugs (compendium
of drugs are found in Table 1).
Collection of disease genes from public databases
The basic gene association approach originated from
Genotator [19] which collected evidence for the associa-
tion of gene to disease from multiple databases and then
scored the evidence thus providing an evidenced-based
ranked list of genes associated with a given disease. Here,
we collected IBD and sibling disease genes from HuGE
Navigator, PharmGKB, GeneCards and Genetic Associa-
tion Database (GAD). We downloaded the PharmGKB
and GAD datasets and ‘scraped’ genes from the HuGE
Navigator and GeneCards web applications. All data was
selected in August, 2010. On the gene collection, we
employed all the variation of synonymous names of IBD
and sibling diseases. The collection of genes were then
merged by matching EntrezGene IDs. If a database did
n o tp r o v i d eag e n e ’sE n t r e z G e n eI D s ,w eu s e dt h e
DAVID bioinformatics tools [29,30] to retrieve the
EntrezGene IDs.
Protein-Protein Interaction network
A Protein-Protein Interaction (PPI) network was produced
by STRING8 (October, 2010) using at least one experi-
mental association result, information from PPI databases,
including additional edges of one path (depth = 2), and
with high confidence (confidence > 0.9). We used CYTOS-
CAPE [31] to visualize the PPI networks.
Semantic similarity between two genes
We employed the same scoring as [32]. First, define
IC(c)=−log(p(c)) (1)
where p(c) is the frequency of annotation of the term
c and its children in the GO graph. Here, Information
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relative to other terms [33]. Second, define the similarity
between two GO terms c1 and c2 as:
SIMterm(c1,c2) = arg max
c∈A(c1,c2)
(IC(c)) (2)
where A(c1,c2) is the set of common ancestors of c1 and
c2.S I M term(c1,c2) is defined as the most informative com-
mon ancestor of c1 and c2 [34,35]. Then, define the simi-
larity between two GO term sets A and B (SIMtermset(A,
B)), assuming that the gene gA and the gene gB are anno-
tated respectively with n and m GO terms as A={ G O 1A,
GO2A,...,GOnA}, B = {GO1B,G O 2B,...,GOmB}. SIMtermset(A,B)
is defined as summation of the maximum similarities
between a term in set A and any of terms in set B, normal-
ized by summation of IC of the terms in set A:
SIMtermset(A,B)=
n 
i=1
arg max
GO∈B
SIMterm(GOiA,GO)
n 
i=1
arg max
GO∈B
SIMterm(GOiA,GO)+
n 
i=1
IC(GOiA)
(3)
P l e a s en o t et h a tSIMtermset(A, B) is not equal to SIM-
termset(B, A). Then the expected similarity SSM between
the gA and the gB is defined as:
SSM(gA,gB)=
SIMtermset(A,B)+SIMtermset(B,A)
2
(4)
(symbol for member of) 0[1]. A pseudo-code for SSM
calculation is available in Additional file 1. We calculated
the random distribution of the SSM score; 1,000 randomly
collected human genes were tested against the drug targets
for IBDmild and IBDsevere separately. Both distributions
showed upper quartile threshold scores to be 0.5 (0.50760
and 0.50940 for IBDmild and IBDsevere respectively), and
we determined that the upper quartile was best suited to
define both those genes most likely closely associated with
the disease but least likely to be unimportant. Conse-
quently, we used the 0.5 threshold as criteria for our SSM
scoring.
Gene score for record frequency
Define Record Frequency RFg as the total frequency of
records of a certain gene related to the sibling disease
(sib) contained in the database (db):
RFg =l o g (

j∈db

i∈sib
RFg(i,j)
NdbNsib
×
Nref
DFg
) (5)
where Ndb is the total number of tested databases (four
in this study: HugeNavigator, PharmGKB, GeneCards,
and GAD), Nsib is the total number of the sibling dis-
eases, Nref is the total number of papers reporting on any
human gene, and DFg is the frequency of papers report-
ing a certain gene. We calculated DFg and Nref by Entrez
Programming Utilities provided by NCBI. When calculat-
ing DFg, we replaced a name of a certain gene with its
s y n o n y m so b t a i n e df r o mac o m p l e t eg e n ei n f o r m a t i o n
table ("Homo_sapiens.gene_info”) provided by NCBI. Nref
was evaluated by the number of papers annotated with
MeSH terms of “homo sapiens” and “gene” or “protein”.
Nref ~2.3 million (Aug 10th, 2010).
Table 1 A list of drugs for Inflammatory Bowel Disease and their indications
IBD state Category Drug name Indication
US UK Japan
Mild Amino-salicylate Mesalazine UC, CD UC, CD UC, CD
Salazo-sulfapyridine UC, CD, RA UC, CD, RA UC, CD, RA
Olsalazine UC UC -
Balsalazide UC UC -
Moderate Immuno-modulators Azathioprine RA, GVHD RA, SLE, DM, AICAH, PM, PV,
PN, AHA ITP
GVHD, CD
Tacrolimus PTR PTR PTR, GVHD, MG, RA, LN, UC
Corticosteroids Budesonide (Entocort only) CD CD -
Prednisolone RA, UC (chronic), Nephrotic Syndrome, Collagen Diseases, Fulminating SLE, Allergic
Conditions, Bronchial Asthma, Acute Skin Diseases, Thrombocytopenia, Organ
transplantation.
Severe Anti-TNF antibody Infliximab UC, CD, RA, PS, AS UC, CD, RA,
PS, AS
UC, CD, RA,
PS, AS, BD
Adalimumab CD, RA, PS, AS CD, RA, PS, AS -
Certolizumab CD, RA RA -
Abbreviations: CD Crohn’s disease, UC Ulcerative colitis, RA Rheumatoid artitis, PS Psoriasis (including PS Psoriatic arthritis), AS Ankylosing spondylitis, BD Bachet
disease, GVHD Graft versus host disease, SLE Systemic lupus erythematosus, DM Dermatomyosis, PM Polymyositis, AICAH Auto-immune chronic active hepatitis, PV
Pemphigus vulgaris, PN Polyarteritis nodosa, AHA Auto-immune haemolytic anaemia, ITP Idiopathic thrombocytopenic purpura, MG Myasthenia gravis, LN Lupus
nephritis, PTR Platelet transfusion refractoriness
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We retrieved 12 data sets from GEO and 13 data sets from
ArrayExpress by a query with keywords of “Crohn’sd i s -
ease, CD, ulcerative colitis, UC, inflammatory bowel dis-
ease, IBD, homo sapiens”. After investigation of individual
data sets, only three of them (GSE6731 [36], GSE9452
[37], and E-TABM-118 [38]) consist of patients with CD
and UC and include patient information on medicinal
drugs the patients took. Consistent with our fundamental
approach, we classified the patients prescribed aminosali-
cylate into “patients in mild state” (IBDmild) and the
patients prescribed anti-TNF antibody into “patients in
severe state” (IBDsevere). Since E-TABM-118 includes
very few patients in the severe state, we focused on differ-
ential expressed gene analysis with GSE6731 and GSE9452
using the “samr” package in R [39] between IBDmild and
IBDsevere patients and data sets. Genes of FDR < 0.05
were selected (2,549 genes from GSE6731 and 17 genes
from GSE9452) and mapped the genes to our PPI network
produced by STRING8 resulting in 28 genes from
GSE6731 (listed in Additional file 2: Table S4) and no
genes from GSE 9452 mapped to the PPI network.
Results
Determination of sibling diseases for the mild and severe
states of IBD
As in autism spectrum disorder [18], we assumed genes
common among the IBD network of sibling diseases
would represent a molecular mechanism essential to all
sibling diseases including IBD. The sibling diseases were
determined as follows.
The World Gastroenterology Organization defines three
categories of malignancy in IBD, mild, moderate, and
severe states in its global guidelines for IBD treatment [4].
There is also clear categorization in drug indication to IBD
according to the malignancy: aminosalicylate drugs for
mild state patients, immunomodulator drugs and corticos-
teroid drugs for moderate state patients, and anti-TNF
antibody drugs for severe state patients (Table 1). We then
assumed the drugs provided the key to determine known
sibling diseases for IBD. Table 1 shows diseases to which
the same drugs as IBD are indicated in US, UK, and Japan.
CD, UC, and RA are representative diseases treated with
the drug of the mild state (aminosalicylate), while PS, AS,
and BD are representative diseases treated using the drug
of the severe state (anti-TNF antibody). Although the
severe state also includes CD, UC, and RA, the three dis-
eases were eliminated from the sibling group for the severe
state (Table 1) to investigate the net difference between the
mild and severe states. We therefore determined these dis-
eases as the sibling diseases of IBD for its mild: IBDmild =
{CD, UC, RA} and severe: IBDsevere = {PS, AS, BD} states
(as used above). The moderate state was neglected from
this study because we aimed at a comparison between the
most extreme malignancy IBD states.
Collection of disease genes from public databases
Figure 1 shows the number of genes related to the two
sibling diseases, IBDmild and IBDsevere. Genes for each
sibling disease (1,264 for IBDmild and 869 for IBDsevere,
Figure 1) were collected from the public databases:
HugeNavigator, GeneCards, PharmGKB, and GAD. For
each gene, g, we calculated the ranking score RFg by the
frequency of the gene in databases and the frequency of
the gene in PubMed according to equation (5). RFg was
calculated for all genes associated with each sibling dis-
ease. We then determined a threshold score for each sib-
ling disease used to exclude genes without significant
evidence supporting their association with the sibling dis-
e a s e .T od e f i n et h et h r e s h o l d s ,w ei d e n t i f i e da l lg e n e si n
the two sibling disease gene sets which have verified asso-
ciation with IBD by direct literature review. We then
scored all verified genes and chose the gene with lowest
score in each sibling gene set (TNF for IBDmild and CRP
for IBDsevere). Applying these thresholds to the RFg
ranked list of sibling genes resulted in 250 and 253 genes
for IBDmild and IBDsevere respectively. The intersection
of the two sibling disease sets was 94 genes.
All genes in the IBDmild and IBDsevere gene sets were
tested for Protein-Protein Interactions (PPIs) with
STRING8 [40] and those with at least one published
experimental result and information from the PPI data-
bases support were included in subsequent HDN analysis.
A total of 146 (IBDmild) and 151 (IBDsevere) genes had at
least one validated PPI relationship (Figure 1). We define
the collective PPI networks as the “HDN” for IBD.
Significant genes in IBDmild and IBDsevere
Our goal is to identify significant genes representing dif-
ferences between IBDmild and IBDsevere.W ef o c u s e d
on drugs that treat either IBDmild or IBDsevere. Amino-
salylate was the drug specific to IBDmild, and anti-TNF
antibody was the drug specific to IBDsevere (Table 1).
In a cell, aminosalylate inhibits PTGS1, PTGS 2, ALOX5,
and PPARG. These four genes were defined as drug tar-
gets for IBDmild in this study. On the other hand, anti-
TNF antibody inhibits TNF receptor 1A and 1B.T h e s e
two genes were defined as drug targets for IBDsevere.
We consider a gene to be functionally similar to these
drug target genes as a significant gene potentially repre-
senting differences between IBDmild and IBDsevere.
Such a functional similarity can be measured by a score
provided by Gene Ontology (GO). There have been
reports on application of the functional similarity score
to the analysis of PPI networks [33-35]. We employed
the GO-based similarity score (SSM in equation (4)) to
Suzuki et al. BMC Medical Genetics 2012, 13:25
http://www.biomedcentral.com/1471-2350/13/25
Page 4 of 10our HDNs to highlight functional similarity of a gene to
the drug targets.
Figure 2 shows the HDNs whose nodes were selected by
the functional similarity of a gene to the drug targets. A
node scored less than 0.5 (upper quartile of the random dis-
tribution of SSM) were eliminated from the HDNs. A trian-
g u l a rn o d ei n d i c a t e sag e n eb e l o n g st ob o t hH D N so f
IBDmild and IBDsevere, while a circular node represents a
gene belongs to either HDN of IBDmild or IBDsevere.
Additional file 3: Table S2 lists the genes consist of the
HDNs. The similarity score in this study showed a mean
score of 0.40050, with a standard deviation of 0.13942, a
maximum score of 0.86640, a minimum score of 0.02972,
and a upper quartile of 0.50760 against IBDmild drug tar-
gets, and a mean score of 0.37570, with a standard devia-
tion of 0.17189, a maximum score of 0.91200, and a
minimum score of 0.02417, and a upper quartile of 0.50940
against IBDsevere drug targets.
Differences between the HDNs of IBDmild and IBDsevere
Table 2 shows the functional classification of genes in the
HDNs of IBDmild and IBDsevere. Both HDNs consist of
similar kinds of functional groups: i.e., inflammation,
innate and acquired immune response, apoptosis, tumor-
igenesis, and tissue remodeling. However, the HDN of
IBDsevere includes genes of tumorigenesis and apoptosis
larger in number than the HDN of IBDmild (encircled by
a green area in Figure 2(A) and 2(B)). The HDN of IBD-
mild also includes some genes of tumorigenesis and
apoptosis, but the genes stay peripherally around a cen-
tral gene group of inflammation and immunoregulation
(encircled by a rose area). In contrast, the HDN of IBDse-
vere includes close interconnection among genes from
the tumorigenesis and apoptosis group. This feature was
not observed in the HDN of IBDmild.
Both in the HDNs of IBDmild and IBDsevere,s o m e
genes of inflammation and immunoregulation have highly
condensed interactions with surrounding genes. Interest-
ingly, numbers of them were detected by the GWAS stu-
dies [8,9] (Additional file 4: Table S3). These genes (IL2,
IL12B, IL23R, IFNG,a n dJAK2) indicate significant func-
tionalities in the IBD pathogenesis. Besides, differentially
expressed gene between IBDmild and IBDsevere are also
included in the condensed interconnections of genes.
Disease name HuGE Navigator PharmGKB Gene Cards GAD
Crohn's disease (CD) 383 89 162 162
Ulcerative colitis (UC) 232 23 796 187
Rheumatoid arthritis (RA) 457 151 106 177
Psoriasis  (PS) 181 52 684 130
Ankylosing spondylitis (AS) 86 5 215 77
Behcet disease (BD) 107 0 95 72
Step 1) The number of genes retrieved from each public database
Step 2) The sibling diseases and the number of genes for each state
Disease state Sibling disease Total gene Threshold Selected genes by RFg score
IBDmild CD, UC, RA 1,264 TNF 250
IBDsevere PS, AS, BD 869 CRP 253
94 genes are common
HDN Total gene  Drug  target Selected genes by SSM score
IDBmild 146
prostaglandin G/H synthetase 1 and 2,  
arachidonate 5-lipoxygenase,  PPARG
46
IDBsevere 151 TNFRSF1A, TNFSRF1B 62
p) g g
Step 3) The number of genes (nodes) in HDNs for IBD and selected genes by SSM score
Figure 1 The number of genes at each step of the analysis.
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Page 5 of 10Figure 2 Protein-protein interactions among the genes with high functional similarities to the drug targets. (A) A network composed of
functionally similar genes to prostaglandin G/H synthetase 1 and 2, arachidonate 5-lipoxygenase, and PPARG, all of which are drug targets for
IBDmild. (B) A network composed of functionally similar genes to TNF receptor 1A and 1B, which are drug targets for IBDsevere. In each network, a
triangle node indicates a gene common to the HDNs of IBDmild and IBDsevere, a circle node indicates a gene specific either the HDN of IBDmild
or IBDsevere. A node bordered with an orange line indicates a gene detected by GWAS. An edge connecting the GWAS genes is also
highlighted in pale orange. A node marked with an arrow indicates a differentially expressed gene in GSE6731. A blue arrow indicates an up-
regulated gene in IBMmild, while a red arrow indicates an up-regulated gene in IBMsevere. Both networks are divided into three portions by
colored areas. The blue area indicates genes relate to tissue remodeling. The green area indicates genes relate to inflammation and
immunoregulation. The rose area indicates genes relate to tumorigenesis and apoptosis.
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by either blue or red arrow in Figure 2), selected by
SAM statistics (FDR < 0.05) on gene expression data of
GSE6731. While the genes of inflammation and immunor-
egulation were up-regulated in IBDmild (IFNG, IL4,a n d
IL17A, indicated by blue arrows), the genes of tumorigen-
esis and apoptosis were up-regulated in IBDsevere (NFKB1
and TGFB1, indicated by red arrows).
The molecular picture of the progression of IBD
IBD is characterized by the progression from early stage
into chronic and more malignant states. The characteristic
is widely used in the clinical treatment of IBD, but its
molecular processes remains unclear. This study provides
a molecular picture for the progression of IBD. The mole-
cular picture tells us a difference between the mild and
severe states, two extreme states in the progression of
IBD. The biological details are described in “Discussion”.
Discussion
Our knowledge driven HDN gene and molecular data-
base systems approach consists of the following steps: 1)
Determination of sibling diseases for IBD based on drug
information, 2) Collection of IBD and sibling disease
genes from multiple databases, 3) Scoring the disease
genes by evidence-based ranking weighted by “the fre-
quency in databases” and “the frequency in PubMed”,4 )
Evaluation of the disease genes for Protein-Protein Inter-
action relations, and 5) Investigation of GO-based func-
tional similarity of drug targets to the putative IBD genes.
We summarized the criteria for our selection of genes
specific to IBDmild and IBDsevere in Table 3. Our results
may lead to an elucidation for IBD pathogenesis that
remains largely unknown.
Sibling diseases, closely aligned to a complex disease
such as IBD, provide a novel opportunity to use compre-
hensive omics data to identify a core biochemical or treat-
ment pathway not previously identified in medical biology.
If correctly defined, a collection of sibling diseases can
‘cover’ the entire pathophysiological process of a target
disease more completely than any one disease. Wall et al.
determined autism sibling diseases based on commonly
involved genes [18]. We defined IBD sibling diseases based
on drug indications. Drugs act on changing pathogenic
states of a disease. Accordingly, it is highly likely that the
sibling diseases share a common molecular mechanism.
This approach may be generalizable if drugs acting on sib-
ling disease states, are available across the developmental
progression of a given central disease.
Figure 2 indicates that the HDNs for IBD change
according to the state of the disease progression. Our
results show that JAK2 and STAT3, which are known to
be associated with IBD [41], are specific to the HDN of
IBDmild (Figure 2(A)) [10]. These genes form the central
Table 2 Functional classification of genes consist of HDNs for IBD
HDN Functional category Gene
IBDmild immunoregulation ICAM1, IL2, IL23A, IL23R, IL4, CRP, IL11,
IL2RA, IL4R, IRAK3, TYK2
innate immunity CD14, TLR2, TLR4, TLR1, TLR6, IFNG, IL8
inflammation and immunoregulation CCL2, IL12B, IL17, IL1A, IL1RN, NFKB1,
NFKBIA, CCL11, CCL26, IL10RA, IL18RAP
inflammation and apoptosis IL1B, IRF5, TNFSF1A, IL15, JAK2, STAT6
cell growth, apoptosis and tumorigenesis TP53, PTPN11, STAT3, TGFB1
atherosclerosis and tissue remodeling SERPINE1, TIMP1, A2M
diabetes related PPARG
prostaglandin biosynthesis PTGS1, PTGS2
IBDsevere immunoregulation ICAM1, IL2, IL23A, IL23R, IL4, B2M, CD28, CX3CL1, CTLA4, HLA-C, KLRC1, IL12A,
IL12RB2, STAT2, STAT4
innate immunity CD14, TLR2, TLR4, IFNG, IL8
inflammation and immunoregulation CCL2, IL12B, IL17, IL1A, IL1RN, NFKB1,
NFKBIA, CCL5, CSF2, IL1R1, IL6, IL6R, IL18, NR3C1
inflammation and apoptosis IL1B, IRF5, TNFSF1A, IL15
apoptosis FASLG, TNFAIP3, TNFRSF1B, TRADD
cell growth and tumorigenesis TP53, IGF1, IGFBP3, TGFB1, TGFBR1, SOCS1
aging and tumorigenesis SOD1, SOD2
atherosclerosis and tissue remodeling SERPINE1, TIMP1, EDN1, MMP3, PLAT, SELE
diabetes related PPARG, LEP, PPARA
We annotated the genes by their functions according to EntrezGene database.
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inflammatory genes (IL1A/1B, IL12B, IL17A, and IL23A/
R), which are common in both HDNs. These suggest that
JAK2 and STAT3 are key factors in the early stage of IBD
pathology. On the other hand, the HDN of IBDsevere
(Figure 2(B)) indicates a relation of IBD to more malig-
nant diseases like cancer. Patients with long-standing
IBD have an increased risk of developing colorectal can-
cer [42]. Such a transition in functional classes of genes
was also observed with differential expressed genes
between IBDmild and IBDsevere obtained by GSE6731
(nodes with arrows in Figure 2).
The HDNs of IBDmild and IBDsevere include 13 genes
obtained by GWAS reported in [8,9]. The 13 genes are
highlighted by colored borders in orange in Figure 2 and
listed in boldfaced in Additional file 3: Table S2. Most of
the genes are interconnected with each other except
ICAM1 and IRF5. All interconnected genes belong to the
early response of inflammation, which includes cytokines,
chemokines, receptors, and cellular signaling molecules.
The other two genes, ICAM1 and IRF5, belong to the late
response of inflammation, i.e., enhancement of immune
response. Our HDNs illustrate what molecules intervene
between the two sibling disease pathways. Both in the
HNDs of IBDmild and IBDsevere, TP53 and NFKB1/
NFKBIA are common to both disease states, indicating
that the transcriptional regulation intervenes between the
early (IBDmild)a n dl a t e( IBDsevere) responses. In this
way, our HDN analysis and approach helps to clarify the
molecular and therefore disease implications of GWAS
candidate genes.
A recent comprehensive review of molecular pathways
for IBD pathogenesis [10] supports characteristic genes
in our HDNs of IBDmild and IBDsevere.T h eg e n e s
characteristic of the HDN of IBDmild (Jak2, Stat3,a n d
IL23) belong to Th17-cell differentiation in [10], and the
genes characteristic of the HDN of IBDsevere (IL12,
IFN-gamma, IL18 and FASLG) belong to Th1-cell driven
responses in [10,36]. The physiological balance between
T h 1a n dT h 1 7m a yb ed e t e r i o r a t e db ye n v i r o n m e n t a l
factors such as intestinal bacteria stress, which even-
tually leads to autoimmune responses composing IBD
(“hygiene hypothesis” introduced by Strachan [43]). Our
HDNs suggest a transition from Th17 to Th1 domi-
nancy along with progression of malignancy [44]. Our
approach stratifying the disease-related genes into IBD-
mild and IBDsevere enables us to infer a clinically signif-
icant transition of a state of a disease such as the Th1/
Th17 transition.
Conclusions
In this study, we employed a knowledge driven human
disease systems approach to analyze IBD, whose patho-
genesis remains largely unknown. Based on drug indica-
tions for IBD, we determined two sibling disease states of
IBD (mild and severe). After ranking the genes by the fre-
quency of the records, we obtained 250 and 253 genes for
IBDmild and IBDsevere, respectively. We calculated func-
tional similarities of these genes with IBD drug targets
and drew their interactions as PPI networks we later
defined as the two sibling disease HDNs. The HDNs
revealed biological and clinical insights into the molecu-
lar differences between IBDmild and IBDsevere.T h e
results demonstrated that knowledge annotation of sib-
ling disease HDNs with focus on high similarity genes is
an effective approach to identify common genes and
pathways important to the complex disease network.
Additional material
Additional file 1: Pseudo-code for SSM calculation.
Additional file 2: Table S4. Differential expressed genes between
IBDmild and IBDsevere. Resulted 28 genes from GSE6731: differentially
expressed between IBDmild and IBDsevere (FDR < 0.05) and mapped to
our PPI network produced by STRING8.
Additional file 3: Table S2. Genes consisting of the HDNs. Genes
consisting of the HDNs of Figure 2 are listed in this Table. These genes
were selected when being functionally similar to the drug targets of
each state (SSM > 0.5), as well as when having PPI connections among
themselves. Accordingly, the genes “common to both HDNs” are
different between IBDmild and IBDsevere, because SSM scoring is different
between the HDNs. Genes are boldfaced when they are susceptibility
loci for IBD detected by GWAS [8,9]. Genes are underlined when they are
selected as differential expressed genes by SAM statistics (FDR < 0.05)
[39] with GSE6731. Abbreviations for gene names are lilsted in Additional
file 5: Table S1.
Additional file 5: Table S1. Abbreviations for gene names. All the
abbreviations for gene names used in this manuscript are listed.
Table 3 Criteria for selection of genes specific to IBDmild and IBDsevere
Criteria for selection No. of IBDmild
genes
No. of IBDsevere
genes
(1) Collect IBD-associated genes from databases for human diseases. 1,264 869
(2) Rank the genes by the frequency of the IBD-association in the databases (equation (5)). Cut off the genes
falling short of the lowest frequency of a gene validated its disease association by literatures (TNF for IBDmild
and CRP for IBDsevere).
250 253
(3) Select the genes interconnected by PPI evidence. 146 151
(4) Rank the genes by GO based similarity score (SSM, equation (4)) to IBD drug targets. Cut off the genes
under the upper quartile of the random distribution of SSM scores against IBD drug targets.
46 62
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Page 8 of 10Additional file 4: Table S3. Bond order of susceptibility gene for
IBD detected by GWAS. GWAS susceptibility genes [8,9] are listed with
their bond order in HDNs of IBDmild and IBDsevere.
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